A therapeutic dosage of glucocorticoid has developed a LC which is an herbal remedy that can effectively reduce Systemic lupus erythematosus patients in clinical trial. This translational research examined the impact of LC on biomarkers of endothelial injury in the enrolled subjects. Fifty seven patients with Systemic lupus erythematosus were randomized to receive standard treatment without or with LC supplements. Blood samples were taken serially for quantification of endothelial progenitor cells, circulating endothelial cells and serological factors. The proportion of endothelial progenitor cells in the placebo group continued to increase during trial and was further elevated after withdrawal of standard treatment. The endothelial progenitor cell ratio of LC group remained stationary during the entire observation period. The circulating endothelial cells ratio in placebo group exhibited an increasing trend whereas that in LC group declined. The ratio of apoptotic circulating endothelial cells had an increasing trend in both groups, to a lesser extent in LC group. After treatment, the levels of VEGF and IL-18 have a trend weakened to a lower level in the LC group than the placebo group. No significant alteration was noted in serum levels of IFN-α, IL-1β and IL-6. The reduction of the steroid dosage by adding LC might be correlated with less extensive endothelial injury in Systemic lupus erythematosus patients.